,5 Nonetheless, the presence of fibrosis at presentation or new onset of fibrotic change in the macular tissues during anti-VEGF therapy is a finding that is associated with worse visual outcomes compared with eyes without macular fibrosis.6, 7, 8, 9. The gene discussed is VEGFA; the disease is fibrosis.